Clinical Commander

Back to dossier
cardio.hypertensive-emergency.maoi-tyramine-crisis.v1PRODUCTION
cardio.hypertensive-emergency.maoi-tyramine-crisis.v1

MAOI–tyramine hypertensive crisis ("cheese effect" — severe occipital headache + HTN crisis + tachycardia + diaphoresis after MAOI + tyramine-rich food or sympathomimetic exposure)

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

MAOI–tyramine crisis = irreversible MAO-A/B inhibition + dietary tyramine (aged cheese, cured meats, etc.) OR sympathomimetic medication → tyramine-driven NE flood from sympathetic terminals → severe HTN crisis with severe occipital headache + tachy + diaphoresis within 30 min – 2 h. Pharmacology pivot: PHENTOLAMINE 5 mg IV q5-15 min titrate (alpha-blocker, cornerstone) OR nicardipine IV (autoregulation-aware alternative); AVOID β-blocker monotherapy (unopposed alpha vasoconstriction worsens HTN); AVOID meperidine (can trigger hyperthermic + serotonin reactions in MAOI); SSRI 14-d washout required before/after irreversible MAOI.

Inputs
5
Actions
0
Advance rule
Set
Advance when

MAOI-tyramine etiology confirmed by history (med + trigger) + clinical features (occipital headache + HTN crisis)

Patient inputs (12)

Older patients on MAOI for treatment-resistant depression more likely; education-failure risk drives dietary lapses

Confirms etiology — irreversible MAOI (phenelzine 15 mg/d, tranylcypromine 30-60 mg/d, isocarboxazid, selegiline transdermal 9-12 mg/24h); reversible MAO-A inhibitor (moclobemide) lower risk; selegiline 6 mg/24h transdermal selective MAO-B has minimal tyramine risk

Confirms trigger — aged cheese, cured meats, fava beans, soy sauce, draft/unpasteurized beer, fermented soy, sauerkraut, OR sympathomimetic medication (pseudoephedrine, phenylephrine, ephedra, amphetamines)

Classic cheese-reaction headache: severe, occipital/throbbing, distinct from migraine; concurrent photophobia + N/V common

Demand ischemia from severe HTN + tachycardia; QTc baseline; baseline for MAOI-related cardiotoxicity assessment

Demand ischemia rule-out (NE surge can drive Type 2 MI in elderly with CAD)

eGFR drives drug dosing for phentolamine + nicardipine; baseline for renal injury assessment

Focal neurologic deficit suggests ICH (cheese reactions can cause ICH per case reports); exclude with CT head

Defines crisis threshold; drives titration of phentolamine IV

Component of MAP; DBP >120 supports crisis criterion + alpha-overdrive severity

Reflex tachycardia from NE surge + risk of demand ischemia; HR >120 plus HTN drives BP target faster

Hyperthermia uncommon in tyramine reactions but possible if serotonin syndrome overlap (MAOI + SSRI/meperidine) → drives differentiation

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningmaoi_tyramine_intracranial_hemorrhage
    New focal neurologic deficit OR sudden severe headache with declining mental status in MAOI-tyramine crisis — ICH (case-reported fatal complication of cheese reactions per Wimbiscus 2010)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmaoi_tyramine_aortic_dissection
    Severe back/chest pain + BP differential between arms or pulse deficit in MAOI-tyramine crisis — dissection from severe HTN (severe HTN is dissection risk factor)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremaoi_meperidine_or_serotonergic_drug_interaction_missed_during_admission_med_rec
    New meperidine, SSRI, SNRI, tramadol, or dextromethorphan ordered for MAOI patient during admission — interaction missed during med-rec — high risk for serotonin syndrome OR hypertensive crisis (FDA boxed warning for meperidine)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremaoi_tyramine_beta_blocker_exposure_error
    β-blocker monotherapy administered in MAOI-tyramine crisis — unopposed alpha vasoconstriction worsens HTN (analogous to pheochromocytoma + cocaine)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemaoi_tyramine_recurrent_crisis_after_dietary_education_failure
    Second tyramine reaction after prior education — implies education failure, low health literacy, or unintentional exposure (hidden tyramine in foods or new sympathomimetic medication)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

MAOI–tyramine HTN crisis — phentolamine IV cornerstone (alpha-blocker) + nicardipine alternative; AVOID β-blocker monotherapy (unopposed alpha); AVOID meperidine (FDA boxed warning in MAOI); strict tyramine diet + sympathomimetic-medication-avoidance education
axis: maoi_tyramine_crisis_pharmacology
Selected axis "MAOI–tyramine HTN crisis — phentolamine IV cornerstone (alpha-blocker) + nicardipine alternative; AVOID β-blocker monotherapy (unopposed alpha); AVOID meperidine (FDA boxed warning in MAOI); strict tyramine diet + sympathomimetic-medication-avoidance education" by default fallback (first axis)
  • phentolamine
    first line
    alpha_adrenergic_blocker
    5 mg IV bolus q5-15 min titrate to SBP <160; typical total 5-20 mg cumulative; can give 1-5 mg increments for fine titration • IV • PRN bolus titrated
    triggers: MAOI_tyramine_HTN_crisis, severe_occipital_headache_with_HTN_after_tyramine_or_sympathomimetic_exposure_in_MAOI_patient
    Wimbiscus Cleve Clin J Med 2010 PMID 21048054 + Fiedorowicz 2004 PMID 15330418 — phentolamine cornerstone for tyramine crisis (reverses NE surge); same drug used for pheochromocytoma crisis (analogous catecholamine-excess physiology)
    rxcui 8153
  • nicardipine
    second line
    dihydropyridine_CCB
    5 mg/h IV titrate q5 min by 2.5 mg/h to max 15 mg/h • IV • continuous
    triggers: phentolamine_unavailable_or_insufficient, sustained_HTN_after_phentolamine_titration
    AHA 2025 HTN guideline + ACC 2017 — preferred IV agent if phentolamine unavailable; titratable + autoregulation-aware; safe in MAOI patients
    rxcui 7396
  • labetalol
    second line
    mixed_alpha_beta_blocker
    Use ONLY AFTER alpha-blockade established with phentolamine; 10-20 mg IV q10 min, max 300 mg • IV • PRN bolus
    triggers: persistent_tachycardia_after_alpha_blockade_with_phentolamine
    AHA 2025 HTN — mixed alpha-beta acceptable AFTER phentolamine controls alpha component (analogous to pheochromocytoma sequencing); tiny beta component initially raises unopposed alpha concern but practical use ok with simultaneous phentolamine
    rxcui 6185
  • esmolol
    add on
    beta1_selective_blocker
    Use ONLY AFTER alpha-blockade with phentolamine; 500 mcg/kg IV bolus then 50-200 mcg/kg/min infusion titrate • IV • continuous infusion
    triggers: persistent_severe_tachycardia_after_alpha_blockade
    Short half-life beta-blocker for HR control AFTER alpha-blockade; same logic as pheochromocytoma
    rxcui 49737
  • acetaminophen
    add on
    analgesic_non_opioid
    650-1000 mg PO/IV q6h • PO/IV • q6h PRN
    triggers: severe_headache_in_tyramine_crisis
    Non-opioid headache control; first-line analgesic in MAOI patients (avoids meperidine + tramadol risks)
    rxcui 161
  • AVOID meperidine
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: MAOI_patient_requiring_analgesia
    FDA boxed warning — meperidine + MAOI = severe hyperthermic + hypertensive + serotonergic reactions; absolute contraindication
  • AVOID β-blocker monotherapy
    contraindication substitute
    do_not_use
    AVOID monotherapy • N/A • N/A
    triggers: MAOI_tyramine_crisis_initial_management
    Unopposed alpha vasoconstriction (analogous to pheochromocytoma + cocaine teaching); β-blocker only AFTER phentolamine alpha-blockade established
  • AVOID sympathomimetics (pseudoephedrine, phenylephrine, ephedra, OTC cold meds)
    contraindication substitute
    do_not_use
    AVOID • N/A • long-term while on MAOI
    triggers: MAOI_patient_lifetime_avoidance
    Sympathomimetics + MAOI = recurrent tyramine-like crises; lifetime avoidance + medication card education
  • AVOID SSRI/SNRI/tramadol/dextromethorphan during MAOI + 14-d washout
    contraindication substitute
    do_not_use
    AVOID without 14-d washout • N/A • long-term
    triggers: MAOI_patient_serotonergic_drug_addition
    Serotonin syndrome risk; mandatory 14-d washout before/after irreversible MAOI; for fluoxetine require 5-wk washout (long half-life)
  • AVOID nitroprusside
    contraindication substitute
    do_not_use
    AVOID prolonged use • N/A • N/A
    triggers: MAOI_tyramine_crisis_BP_control
    Cyanide accumulation with prolonged infusion; nicardipine preferred

outpatient playbook — drug actions (3)

  1. 1. continue HTN regimen (MAOI-safe)
    rxcui 17767
    Amlodipine 5-10 ± lisinopril ± chlorthalidone • PO • daily
    trigger: Stable maintenance
    ACC/AHA 2025 HTN — these classes safe in MAOI
  2. 2. continue MAOI per psychiatry OR alternative class
    rxcui 8123
    Per psychiatry plan • PO/transdermal • per regimen
    trigger: Depression treatment
    Per individualized psychiatry plan
  3. 3. maintain MAOI-safe analgesia
    rxcui 161
    Acetaminophen + topical NSAIDs; AVOID tramadol/meperidine • PO/topical • as needed
    trigger: Chronic pain
    Lifetime MAOI-safe analgesia

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Irreversible MAOI (phenelzine, tranylcypromine, isocarboxazid, selegiline transdermal high-dose) + tyramine-rich food (aged cheese, cured meats, fava beans, soy sauce, draft beer, fermented foods) OR sympathomimetic medication (decongestant, ephedra, OTC cold med) within 30 min – 2 h (Wimbiscus Cleve Clin J Med 2010 PMID 21048054; Shulman J Clin Psychiatry 2003 PMID 14728101); Severe occipital headache + SBP ≥180/DBP ≥120 + diaphoresis + tachycardia + photophobia within 30 min – 2 h of MAOI + tyramine/sympathomimetic exposure — classic "cheese reaction"; Patient on irreversible MAOI receiving meperidine, SSRI, SNRI, tramadol, or dextromethorphan — drug-drug interaction with potential for tyramine-like surge or serotonin syndrome overlap.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**MAOI–tyramine hypertensive crisis ("cheese effect" — severe occipital headache + HTN crisis + tachycardia + diaphoresis after MAOI + tyramine-rich food or sympathomimetic exposure)** (cardio.hypertensive-emergency.maoi-tyramine-crisis.v1).
Scope: MAOI–tyramine crisis = irreversible MAO-A/B inhibition + dietary tyramine (aged cheese, cured meats, etc.) OR sympathomimetic medication → tyramine-driven NE flood from sympathetic terminals → severe HTN crisis with severe occipital headache + tachy + diaphoresis within 30 min – 2 h. Pharmacology pivot: PHENTOLAMINE 5 mg IV q5-15 min titrate (alpha-blocker, cornerstone) OR nicardipine IV (autoregulation-aware alternative); AVOID β-blocker monotherapy (unopposed alpha vasoconstriction worsens HTN); AVOID meperidine (can trigger hyperthermic + serotonin reactions in MAOI); SSRI 14-d washout required before/after irreversible MAOI.

No severity triggers fired against current inputs.

Plan

Regimen axis: **MAOI–tyramine HTN crisis — phentolamine IV cornerstone (alpha-blocker) + nicardipine alternative; AVOID β-blocker monotherapy (unopposed alpha); AVOID meperidine (FDA boxed warning in MAOI); strict tyramine diet + sympathomimetic-medication-avoidance education**.
1. phentolamine 5 mg IV bolus q5-15 min titrate to SBP <160; typical total 5-20 mg cumulative; can give 1-5 mg increments for fine titration IV PRN bolus titrated (alpha_adrenergic_blocker, first line) — Wimbiscus Cleve Clin J Med 2010 PMID 21048054 + Fiedorowicz 2004 PMID 15330418 — phentolamine cornerstone for tyramine crisis (reverses NE surge); same drug used for pheochromocytoma crisis (analogous catecholamine-excess physiology)
2. nicardipine 5 mg/h IV titrate q5 min by 2.5 mg/h to max 15 mg/h IV continuous (dihydropyridine_CCB, second line) — AHA 2025 HTN guideline + ACC 2017 — preferred IV agent if phentolamine unavailable; titratable + autoregulation-aware; safe in MAOI patients
3. labetalol Use ONLY AFTER alpha-blockade established with phentolamine; 10-20 mg IV q10 min, max 300 mg IV PRN bolus (mixed_alpha_beta_blocker, second line) — AHA 2025 HTN — mixed alpha-beta acceptable AFTER phentolamine controls alpha component (analogous to pheochromocytoma sequencing); tiny beta component initially raises unopposed alpha concern but practical use ok with simultaneous phentolamine
4. esmolol Use ONLY AFTER alpha-blockade with phentolamine; 500 mcg/kg IV bolus then 50-200 mcg/kg/min infusion titrate IV continuous infusion (beta1_selective_blocker, add on) — Short half-life beta-blocker for HR control AFTER alpha-blockade; same logic as pheochromocytoma
5. acetaminophen 650-1000 mg PO/IV q6h PO/IV q6h PRN (analgesic_non_opioid, add on) — Non-opioid headache control; first-line analgesic in MAOI patients (avoids meperidine + tramadol risks)
6. AVOID meperidine AVOID N/A N/A (do_not_use, contraindication substitute) — FDA boxed warning — meperidine + MAOI = severe hyperthermic + hypertensive + serotonergic reactions; absolute contraindication
7. AVOID β-blocker monotherapy AVOID monotherapy N/A N/A (do_not_use, contraindication substitute) — Unopposed alpha vasoconstriction (analogous to pheochromocytoma + cocaine teaching); β-blocker only AFTER phentolamine alpha-blockade established
8. AVOID sympathomimetics (pseudoephedrine, phenylephrine, ephedra, OTC cold meds) AVOID N/A long-term while on MAOI (do_not_use, contraindication substitute) — Sympathomimetics + MAOI = recurrent tyramine-like crises; lifetime avoidance + medication card education
9. AVOID SSRI/SNRI/tramadol/dextromethorphan during MAOI + 14-d washout AVOID without 14-d washout N/A long-term (do_not_use, contraindication substitute) — Serotonin syndrome risk; mandatory 14-d washout before/after irreversible MAOI; for fluoxetine require 5-wk washout (long half-life)
10. AVOID nitroprusside AVOID prolonged use N/A N/A (do_not_use, contraindication substitute) — Cyanide accumulation with prolonged infusion; nicardipine preferred

Setting playbook (outpatient) — Long-term PCP + psychiatry + dietitian coordination — sustained tyramine + medication interaction avoidance, BP <130/80, stable depression treatment, safer-alternative regimen if MAOI tapered
11. continue HTN regimen (MAOI-safe) Amlodipine 5-10 ± lisinopril ± chlorthalidone PO daily — Stable maintenance (ACC/AHA 2025 HTN — these classes safe in MAOI)
12. continue MAOI per psychiatry OR alternative class Per psychiatry plan PO/transdermal per regimen — Depression treatment (Per individualized psychiatry plan)
13. maintain MAOI-safe analgesia Acetaminophen + topical NSAIDs; AVOID tramadol/meperidine PO/topical as needed — Chronic pain (Lifetime MAOI-safe analgesia)

Non-pharmacologic actions:
- Sustained engagement with psychiatry + dietitian
- MedicAlert bracelet on person at all times
- Annual medication review with pharmacy
- Education reinforcement re: travel + new prescriber communication (carry medication card)

AVOID / contraindication checks:
- Meperidine_AVOID_in_MAOI (FDA boxed warning — hyperthermic + hypertensive crisis)
- Beta_blocker_monotherapy_avoid_initial_in_tyramine_crisis (unopposed alpha)
- Sympathomimetic_AVOID_lifetime_on_MAOI (pseudoephedrine, phenylephrine, ephedra, OTC cold meds, decongestants)
- SSRI_SNRI_tramadol_dextromethorphan_AVOID_or_14d_washout (serotonin syndrome)
- Fluoxetine_requires_5wk_washout_before_MAOI (long half life)
- Nitroprusside_avoid_prolonged_use (cyanide)
- Tyramine_rich_food_avoid_lifetime_on_irreversible_MAOI (cheese reaction)

Monitoring

Regimen monitoring:
- continuous ECG q15min BP (AHA 2025 HTN)
- serial troponin q3-6h x2 if elderly or CAD (demand ischemia rule-out)
- serial neuro exam q2h x12h (ICH risk in cheese reaction)
- q4h pain score for headache (severity tracking)
- temperature q15-30min (rule out serotonin overlap if hyperthermic)
- UOP target >0.5mL/kg/h
- cardiac exam for new murmur or acute HF signs

Setting (outpatient) monitoring:
- Quarterly BP + medication reconciliation + dietary check
- Annual ECG + lipid + A1c
- Mental health follow-up per psychiatry

Follow-up plan: COMPREHENSIVE TYRAMINE-RESTRICTED DIET EDUCATION (handout + dietitian consult; high-tyramine foods to AVOID: aged cheeses, cured meats, fava beans, soy sauce, draft beer, sauerkraut, fermented soy, miso, tempeh, marmite/vegemite, tap beer; safe-in-moderation: pasteurized cheese, fresh meat, processed cheese); MEDICATION INTERACTION LIST education (AVOID sympathomimetics — pseudoephedrine, phenylephrine, ephedra, OTC cold meds, decongestants; AVOID meperidine — FDA boxed warning; AVOID SSRI/SNRI/tramadol/dextromethorphan during MAOI + 14-d washout); psychiatry consultation re: continuing MAOI vs alternative (consider switch to MAOI-B selective transdermal selegiline if low-dose tolerated, OR switch to other antidepressant class with appropriate washout); if MAOI required to continue, dietitian referral + medication card carried + family education + MedicAlert bracelet; outpatient PCP + psychiatry follow-up within 1-2 weeks
- Close-out criterion: dietary education completed + medication card issued + psychiatry follow-up booked + safer regimen considered

Monitoring phase: Continuous ECG + telemetry; q15-30 min BP; serial troponin q3-6h × 2 if elderly or CAD; serial neuro exam q2h × 12 h; pain score; UOP

Disposition

Current setting: outpatient — Long-term PCP + psychiatry + dietitian coordination — sustained tyramine + medication interaction avoidance, BP <130/80, stable depression treatment, safer-alternative regimen if MAOI tapered

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + psych.depression.core.v1 for chronic management

Escalation triggers (move to higher acuity):
- Recurrent tyramine crisis → ED + flag offending agent + reinforce education
- BP rebound → urgent visit
- New depression/SI → emergent psychiatry
- New prescription needing interaction check → pharmacy MTM

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] New focal neurologic deficit OR sudden severe headache with declining mental status in MAOI-tyramine crisis — ICH (case-reported fatal complication of cheese reactions per Wimbiscus 2010)
- [LIFE_THREATENING] Severe back/chest pain + BP differential between arms or pulse deficit in MAOI-tyramine crisis — dissection from severe HTN (severe HTN is dissection risk factor)
- [SEVERE] New meperidine, SSRI, SNRI, tramadol, or dextromethorphan ordered for MAOI patient during admission — interaction missed during med-rec — high risk for serotonin syndrome OR hypertensive crisis (FDA boxed warning for meperidine)

Citations

- Wimbiscus Cleve Clin J Med 2010 (PMID 21048054) — MAOI safety + tyramine reactions + drug interactions; 2025 ACC/AHA HTN (Whelton); FDA boxed warning meperidine + MAOI [PMID:21048054](https://pubmed.ncbi.nlm.nih.gov/21048054/)
- Cited evidence (PMID 14728101) [PMID:14728101](https://pubmed.ncbi.nlm.nih.gov/14728101/)
- Cited evidence (PMID 15330418) [PMID:15330418](https://pubmed.ncbi.nlm.nih.gov/15330418/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 10972386) [PMID:10972386](https://pubmed.ncbi.nlm.nih.gov/10972386/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Wimbiscus Cleve Clin J Med 2010 (PMID 21048054) — MAOI safety + tyramine reactions + drug interactions; 2025 ACC/AHA HTN (Whelton); FDA boxed warning meperidine + MAOI — PMID:21048054
  • Cited evidence (PMID 14728101) — PMID:14728101
  • Cited evidence (PMID 15330418) — PMID:15330418
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 10972386) — PMID:10972386